Cargando…
Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study
BACKGROUND: Patients presenting with early-stage melanoma (AJCC pT1b-pT2a) reportedly have a relatively low risk of a positive SNB (~5–10%). Those patients are usually found to have low-volume metastatic disease after SNB, typically reclassified to AJCC stage IIIA, with an excellent prognosis of ~90...
Autores principales: | Moncrieff, Marc D., Lo, Serigne N., Scolyer, Richard A., Heaton, Martin J., Nobes, Jenny P., Snelling, Andrew P., Carr, Michael J., Nessim, Carolyn, Wade, Ryckie, Peach, A. Howard, Kisyova, Rumi, Mason, Jennifer, Wilson, Ewan D., Nolan, Grant, Pritchard Jones, Rowan, Sondak, Vernon K., Thompson, John F., Zager, Jonathan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356930/ https://www.ncbi.nlm.nih.gov/pubmed/35562521 http://dx.doi.org/10.1245/s10434-022-11761-4 |
Ejemplares similares
-
Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009) -
Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients
por: Hussain, Zahra, et al.
Publicado: (2022) -
Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes
por: Moncrieff, Marc, et al.
Publicado: (2021) -
Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
por: Wade, Ryckie G., et al.
Publicado: (2018) -
Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma
por: Sondak, Vernon K., et al.
Publicado: (2012)